ORMD-0801 for Diabetes
Trial Summary
Will I have to stop taking my current medications?
The trial does not require you to stop taking your current glucose-lowering medications if you are on a stable dose of up to three specific types. However, if you are using injected insulin or certain other medications, you may need to stop those before joining the trial.
What data supports the effectiveness of the drug ORMD-0801 for diabetes?
What makes the drug ORMD-0801 unique for treating type 2 diabetes?
What is the purpose of this trial?
ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering medications. A total of three hundred subjects will be enrolled in this study and will be required to complete this thirty-four-week clinical trial.
Research Team
Miriam Kidron, Ph.D.
Principal Investigator
Oramed, Ltd.
Eligibility Criteria
This trial is for people with Type 2 Diabetes Mellitus who haven't had much success with other glucose-lowering meds. They'll be part of a study lasting about 34 weeks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive double-blind treatment with ORMD-0801 or placebo for 26 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ORMD-0801
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oramed, Ltd.
Lead Sponsor
InClin, Inc.
Collaborator